In last trading session, Caribou Biosciences Inc (NASDAQ:CRBU) saw 0.74 million shares changing hands with its beta currently measuring 2.29. Company’s recent per share price level of $1.01 trading at $0.02 or 2.49% at ring of the bell on the day assigns it a market valuation of $93.93M. That closing price of CRBU’s stock is at a discount of -488.12% from its 52-week high price of $5.94 and is indicating a premium of 2.97% from its 52-week low price of $0.98. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.95 million shares which gives us an average trading volume of 1.33 million if we extend that period to 3-months.

For Caribou Biosciences Inc (CRBU), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.48 in the current quarter.

Caribou Biosciences Inc (NASDAQ:CRBU) trade information

Upright in the green during last session for gaining 2.49%, in the last five days CRBU remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $1.01 price level, adding 12.93% to its value on the day. Caribou Biosciences Inc’s shares saw a change of -36.48% in year-to-date performance and have moved -12.93% in past 5-day. Caribou Biosciences Inc (NASDAQ:CRBU) showed a performance of -21.71% in past 30-days. Number of shares sold short was 10.22 million shares which calculate 7.92 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 66.33% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -197.03% in reaching the projected high whereas dropping to the targeted low would mean a loss of -197.03% for stock’s current value.

Caribou Biosciences Inc (CRBU) estimates and forecasts

This year revenue growth is estimated to fall -9.80% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.18M for the same. And 4 analysts are in estimates of company making revenue of 1.23M in the next quarter. Company posted 2.43M and 3.46M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -33.41% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -15.45% while estimates for its earnings growth in next 5 years are of -22.05%.

Caribou Biosciences Inc (NASDAQ:CRBU)’s Major holders

Insiders are in possession of 10.08% of company’s total shares while institution are holding 61.61 percent of that, with stock having share float percentage of 68.52%. Investors also watch the number of corporate investors in a company very closely, which is 61.61% institutions for Caribou Biosciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CRBU for having 6.95 million shares of worth $11.39 million. And as of 2024-06-30, it was holding 7.7801 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.54 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.0891 of outstanding shares, having a total worth of $7.45 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.7 shares of worth $2.73 million or 2.91% of the total outstanding shares. The later fund manager was in possession of 2.29 shares on Dec 31, 2024 , making its stake of worth around $2.31 million in the company or a holder of 2.46% of company’s stock.